St. John's, Canada Clinical Trials

A listing of St. John's, Canada clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 96 clinical trials
A Phase III Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis (STARSCAPE)

This phase III study will evaluate the efficacy, safety and pharmacokinetics (PK) of recombinant human pentraxin-2 (rhPTX-2; PRM-151) zinpentraxin alfa, compared with placebo in participants with idiopathic pulmonary fibrosis (IPF).

lung biopsy
idiopathic pulmonary fibrosis
carbon monoxide
Eastern Health - General Hospital
 (1.6 away) Contact site
  • 24 Oct, 2022
  • +329 other locations
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of MEDI3506 in Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease and Chronic Bronchitis (FRONTIER 4) (FRONTIER-4)

This is a research study to determine the efficacy and safety of investigational drug MEDI3506 for the treatment of adult subjects with Chronic Obstructive Pulmonary Disease and Chronic Bronchitis.

pulmonary disease
body mass index
Research Site
 (866.5 away) Contact site
  • 21 Oct, 2022
  • +86 other locations
A Phase II Multicenter, Randomized, Double-Blind, 12-Week Treatment, 3-Arm, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)

This study will investigate the efficacy, safety, tolerability, and pharmacokinetics of RO7017773 in participants aged 15-45 years who have been diagnosed with ASD with a score of >/=50 on the Wechsler Abreviated Scale of Intelligence (WASI-II).

Janeway Childrens Health; and Rehabilitation Centre
 (1.6 away) Contact site
  • 23 Oct, 2022
  • +19 other locations
ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination With Azacitidine Versus Azacitidine Plus Placebo in Treatment-naïve Patients With Higher Risk Myelodysplastic Syndrome (ENHANCE)

The primary objective of this study is to evaluate the efficacy of magrolimab in combination with azacitidine compared to that of azacitidine plus placebo in previously untreated participants with intermediate/high/very high risk myelodysplastic syndrome (MDS) by Revised International Prognostic Scoring System (IPSS-R) as measured by complete remission (CR) and overall …

high risk myelodysplastic syndrome
QEII Health Sciences Centre
 (555.8 away) Contact site
  • 23 Oct, 2022
  • +169 other locations
Remote Patient Management of CIEDs - Brady Devices (RPM CIED Brady)

While remote monitoring (RM) technology is currently available and has permitted surveillance and device assessment from any patient location, the use has been inconsistent in Canada, where only 8500 out of a potential 120 000 patients with cardiac implantable electronic devices (CIEDs) are enrolled in this program. This technology is …

QEII Health Sciences Center
 (555.8 away) Contact site
  • 04 Oct, 2022
  • +4 other locations
A Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis (Ocarina II)

This study will evaluate the pharmacokinetics, pharmacodynamics, safety, immunogenicity, and radiological and clinical effects of subcutaneous (SC) administration of ocrelizumab compared with the intravenous (IV) infusion of ocrelizumab in patients with either relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS).

disease or disorder
Memorial University of Newfoundland (MUN) - Faculty of Medicine - St. Clare's Mercy Hospital (SCM)
 (1.5 away) Contact site
  • 11 Oct, 2022
  • +35 other locations
Aveir DR i2i Study

Prospective, non-randomized, multi-center, international study designed to evaluate the safety and effectiveness of the Aveir™ Dual-Chamber (DR) Leadless Pacemaker system.

HSC, Eastern Health
 (1.6 away) Contact site
  • 07 Oct, 2022
  • +76 other locations
SurgeCon: An Emergency Department Surge Management Platform (SurgeCon)

Wait times and overcrowding are challenging emergency departments (EDs) around the world. Several countries with advanced healthcare systems cannot keep pace with patient demand, and Canada ranks among the longest wait times compared to peer-industrialized countries. In fact, the Canadian Institute for Health Information (CIHI) identified an 11% increase in …

St. Clare's Mercy Hospital
 (0.4 away) Contact site
  • 07 Oct, 2022
  • +3 other locations
SyncAV Post-Market Trial (SyncAV)

The SyncAV Post-Market Trial is a prospective, randomized, multi-center trial performed to determine if cardiac resynchronization therapy (CRT) devices programmed with SyncAV ON improve long-term CRT response compared to devices programmed with conventional CRT through evaluation of changes in left ventricular (LV) reverse remodeling.

heart failure
implantable cardioverter-defibrillators
beta blockers
cardiac resynchronization therapy
HSC, Eastern Health
 (1.6 away) Contact site
  • 07 Oct, 2022
  • +100 other locations
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis (PACIFICA)

This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) therapy in patients with MF and severe thrombocytopenia (platelet count <50,000/μL). Approximately 399 patients in total will be enrolled, randomized 2:1 to either pacritinib (approximately 266 patients) or …

left upper quadrant pain
blood blast count
renal function
ct scan
Eastern Regional Health Authority
 (1.6 away) Contact site
  • 07 Oct, 2022
  • +74 other locations